Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Biological age & clocks
Research brief

15-year epigenetic aging trajectories and midlife brain health in 2,833 adults

In 2,833 middle-aged adults, faster 15-year epigenetic aging trajectories were associated with worse cognition, while slower trajectories were linked to cognitive resilience and more favorable Alzheimer biomarker profiles. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The study analyzed 2,833 middle-aged adults with at least three DunedinPACE epigenetic clock measurements over 15 years. [1]

  2. Fast Agers had slopes more than 1 standard deviation above the mean and showed worse processing speed, memory, executive function and global cognition than Typical Agers. [1]

  3. Slower biological aging trajectories were associated with cognitive resilience and more favorable Alzheimer disease biomarker profiles. [1]

The source at a glance

Study type / format
Observational study reported in an abstract
Population / context
2,833 middle-aged adults, mean baseline age 40 years, 59% female and 44% Black.
Summary based on
Study abstract
Publication status
Preprint · peer-review status not confirmed
Original publication
July 18, 2026

Trajectories over 15 years in midlife adults

The study asked whether changes in biological aging over time, not just a single measurement, relate to brain health. It analyzed 2,833 middle-aged adults with a mean baseline age of 40 years; 59% were female and 44% Black. Participants had at least three DunedinPACE measurements, an epigenetic clock based on DNA methylation, collected over 15 years. The authors note that most earlier studies used single-time-point clock measurements rather than dynamic change over time.

Supporting source [1]

Fast versus typical versus slow agers compared

Using mixed-effects modeling, the researchers derived individual slopes of epigenetic aging and grouped participants: Fast Agers had slopes more than 1 standard deviation above the mean, Slow Agers below, and Typical Agers in between. Compared with Typical Agers, Fast Agers showed worse processing speed, memory, executive function and global cognition. Trajectories were associated with multiple cognitive domains and Alzheimer disease biomarkers. Slower agers showed cognitive resilience and more favorable biomarker profiles.

Supporting source [1]

Associations, not causes, from an abstract

The authors describe these as associations: faster epigenetic aging trajectories went together with worse cognitive performance, and slower trajectories with resilience. The design is observational, so it does not show that epigenetic aging causes cognitive differences. The abstract reports the sample, the 15-year measurement window and the grouping, but gives no effect sizes or confidence intervals. Only the abstract was reviewed; the full text was not reviewed.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. This is an observational study reporting associations, not causes. The abstract gives no effect sizes or confidence intervals.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Epigenetic Clock Trajectories and Brain Health in Midlife

Boeriu AI, Andrews SJ, Hoang T, Bae S, Yaffe K. · europepmc.org · July 18, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    2,833 middle-aged adults
  2. Finding 2 ↑

    Fast Agers (slopes > 1 SD above
  3. Finding 3 ↑

    cognitive resilience and more favorable AD biomarker

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…